Cassava Sciences | PTIE - Cash And Equivalent


Cassava Sciences reported $86.57M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Amgen USD 13.99B 1.95B Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
Cara Therapeutics USD 19.85M 883K Mar/2026
Cassava Sciences USD 86.57M 8.93M Mar/2026
Eisai JPY 245.42B 56.22B Mar/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Geron USD 62.64M 6.25M Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Novartis USD 7.62B 739M Jun/2026
Novavax USD 191.46M 36.9M Jun/2026
Pfizer USD 976M 727M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025